Just popping in with an update. I went to see a local dermatologist who is affiliated with a local university Myositis Center. She did a detailed exam and confirmed I most definitely have the disease, despite no muscle involvement. She said I have EVERY possible skin manifestation of DM -- she found rash in areas I didn't even know I had. She said although I seem stable/smoldering for now, she predicts I will "flare like crazy by summer" with extra sun exposure. She agreed with my rheumatologist, that I need add a new immunosuppressant in order to taper off of prednisone, or risk having a dangerous yo-yo cycle of prednisone. My choices are apparently methotrexate and/or Cellcept, even though IVIG infusions ($$$) are most effective for the rash.
Well, I'm not willing to be on 2 forms of reliable birth control to accept those meds, so I'd need my tubes tied first. Then there's the whole lymphoma risk, given my past EBV. Then there's the hairloss and flu symptoms with methotrexate. Then most people I know on meth get shingles and other opportunistic infections. I'm just not ready...
So I've been reading a lot about LDN - Low Dose Naltrexone. I know several people with DM who got relief with it, and much quicker than the 3-6 months required on meth or Cellcept (if they even help). So I called my long-lost Integrative Medicine doc, found out he does prescribe it, and made an appt for Feb 12. I can't wait!!
LDN has very few side effects, mostly disturbed sleep and vivid dreams, so I will start off on a very low dose.
LDN was recently proven effective in treating Crohn's disease too!
http://download.abstractcentral.com/DDW ... w/646.html
Naltrexone Therapy Improves Activity and Promotes Mucosal Healing in Active Crohn's Disease: a Placebo-Controlled Trial
Jill P. Smith1, Sandra I. Bingaman1, Francesca Ruggiero2, David T. Mauger3, Aparna Mukherjee1, Christopher O. McGovern1, Ian S. Zagon4
1. GI and Hepatology, Medicine, Pennsylvania State University, Hershey, PA, United States, 2. Pathology, Pennsylvania State University, Hershey, PA, United States, 3. Public Health Sciences, Pennsylvania State University, Hershey, PA, United States, 4. Neural & Behavioral Sciences, Pennsylvania State University, Hershey, PA, United States
Background: Accumulating evidence supports a role for endogenous opioid peptides in the development or perpetuation of inflammation. It is hypothesized that the endogenous opioid system plays a role in inflammatory bowel disease, and disruption of the opioid-opioid receptor interaction will reverse inflammation and promote mucosal healing. Methods: A randomized placebo-controlled double blinded study was designed to test the efficacy and safety of an opioid antagonist, naltrexone, in adults with active Crohn’s disease. Patients with confirmed Crohn’s disease and a Crohn’s Disease Activity Index score (CDAI) of at least 220 were randomized to naltrexone (4.5 mg daily) or placebo by mouth daily for 12-weeks. Subsequently, those who had received placebo were treated with naltrexone and those randomized to naltrexone continued on naltrexone for an additional 12 weeks to assess safety and maintenance of response for extended duration. Colonoscopies with biopsies were performed at baseline, weeks-12, and 24 to determine endoscopic and histologic scores by persons blinded to the treatments. The primary outcomes included the CDAI, endoscopic, and histologic inflammatory scores. Other outcomes included quality of life (QOL) according to the IBDQ and SF-36 surveys, and laboratory tests for safety. Results: Forty patients were enrolled and randomized into the study. Baseline CDAI scores (346±16.4) indicated moderate to severe disease. CDAI scores decreased significantly from baseline (p<0.001) in those treated with naltrexone, but not in placebo treated controls. Eighty-two percent of the naltrexone-treated subjects had at least a 70-point drop in the CDAI score indicative of a response and 45% achieved clinical remission (CDAI < 150). Endoscopy and histology inflammatory scores improved in naltrexone treated subjects (p=0.0019) with evidence of decreased mucosal inflammation, and restored crypt architecture. No endoscopic or histological change was found in placebo treated controls. No significant changes were noted in laboratory parameters or QOL surveys. Patients in the placebo group reported increased fatigue compared to naltrexone treated subjects (p=0.04) and two naltrexone-treated subjects had transient mild elevation in liver transaminases which resolved without interruption of therapy. Conclusion: Naltrexone induces mucosal healing and decreases CDAI scores in subjects with moderate to severe Crohn’s disease with minimal side effects recorded. Strategies to alter the endogenous opioid system provide promise for a novel treatment of inflammatory bowel disease in the future. (Supported by BMRP IBD-0180R and NIH DK073614).